Compare DSP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | AQST |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.6M | 529.4M |
| IPO Year | 2021 | 2007 |
| Metric | DSP | AQST |
|---|---|---|
| Price | $12.82 | $5.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $17.81 | $9.00 |
| AVG Volume (30 Days) | 233.0K | ★ 3.6M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | $67,430,000.00 |
| Revenue This Year | $20.27 | $10.08 |
| Revenue Next Year | $16.88 | $49.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | 0.77 |
| 52 Week Low | $8.11 | $2.94 |
| 52 Week High | $14.80 | $7.55 |
| Indicator | DSP | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 59.16 |
| Support Level | $10.36 | $3.70 |
| Resistance Level | $13.36 | $5.10 |
| Average True Range (ATR) | 0.58 | 0.25 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 45.34 | 64.38 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.